[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Inoue J, Misawa A, Tanaka Y, Ichinose S, Sugino Y, Hosoi H, Sugimoto T, Imoto I, Inazawa J: Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas. PLoS One; 2009;4(9):e7099
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroblastoma (NB) is the most frequently occurring solid tumor in children, and shows heterogeneous clinical behavior.
  • Favorable tumors, which are usually detected by mass screening based on increased levels of catecholamines in urine, regress spontaneously via programmed cell death (PCD) or mature through differentiation into benign ganglioneuroma (GN).
  • In contrast, advanced-type NB tumors often grow aggressively, despite intensive chemotherapy.
  • Understanding the molecular mechanisms of PCD during spontaneous regression in favorable NB tumors, as well as identifying genes with a pro-death role, is a matter of urgency for developing novel approaches to the treatment of advanced-type NB tumors.
  • Thus LAPTM5-mediated PCD is closely associated with the spontaneous regression of NBs and opens new avenues for exploring innovative clinical interventions for this tumor.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis. Autophagy. Catecholamines / metabolism. Cell Line, Tumor. Child. DNA Methylation. Down-Regulation. Humans. Up-Regulation

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6286-91 [11959917.001]
  • [Cites] Oncogene. 2008 Oct 27;27(50):6434-51 [18955971.001]
  • [Cites] J Exp Med. 2003 May 19;197(10):1323-34 [12756268.001]
  • [Cites] Lancet Oncol. 2003 Aug;4(8):472-80 [12901961.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):559-63 [15245590.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):679-82 [15390301.001]
  • [Cites] Cancer. 1977 Nov;40(5):2256-63 [922665.001]
  • [Cites] Lancet. 1994 Sep 24;344(8926):869-70 [7916408.001]
  • [Cites] J Pediatr Surg. 1995 Jun;30(6):805-8 [7666311.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4664-9 [7553646.001]
  • [Cites] Virchows Arch. 1995;427(2):167-73 [7582247.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):225-30 [8531999.001]
  • [Cites] Genomics. 1996 Jul 15;35(2):328-37 [8661146.001]
  • [Cites] J Pediatr Surg. 1996 Feb;31(2):251-7 [8938353.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):209-15 [9049850.001]
  • [Cites] Br J Cancer. 1997;75(8):1185-94 [9099968.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1265-9 [9552024.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):18966-73 [9668075.001]
  • [Cites] Cesk Patol. 1998 Nov;34(4):123-30 [9929939.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2307-12 [10344734.001]
  • [Cites] J Pediatr Surg. 2005 Feb;40(2):359-63 [15750929.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10233-42 [16288011.001]
  • [Cites] J Cell Biol. 2005 Nov 21;171(4):603-14 [16286508.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):886-97 [16239905.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):249-57 [16434901.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):101-25 [16412578.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):885-9 [16625204.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):880-4 [16625205.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):631-45 [17116753.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2106-20 [17586306.001]
  • [Cites] J Biol Chem. 2007 Aug 17;282(33):24131-45 [17580304.001]
  • [Cites] Nat Protoc. 2007;2(8):1931-6 [17703204.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6456-68 [17438526.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2861-73 [18006683.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):42-4 [11464902.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):319-21 [11880464.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):358-68 [11880474.001]
  • [Cites] Oncogene. 2007 Nov 22;26(53):7401-13 [17533365.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1504-10 [18349403.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(8):1494-508 [18203646.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 2;100(13):940-9 [18577749.001]
  • [Cites] Immunity. 2008 Jul 18;29(1):33-43 [18619870.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6623-33 [18701486.001]
  • [Cites] J Biol Chem. 2008 Sep 5;283(36):24426-34 [18614535.001]
  • [Cites] Nat Rev Neurosci. 2008 Oct;9(10):741-5 [18769444.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • (PMID = 19787053.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Catecholamines; 0 / Membrane Proteins; 179801-28-6 / LAPTM5 protein, human
  • [Other-IDs] NLM/ PMC2746316
  •  go-up   go-down


2. Hussein HA, Goda HA: Paravertebral neurogenic tumors with intraspinal extension: preoperative evaluation and surgical approach. J Egypt Natl Canc Inst; 2009 Mar;21(1):12-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had CT with guided biopsy and MRI to evaluate extent of tumor bone invasion, intraspinal component, to decide surgical approach and the need for spine fixation.
  • Benign schwannoma were diagnosed in 5 cases, malignant schwannoma in 3, neurofibromatosis in one case, neuroblastoma in 3 cases, ganglioneuroblastoma in 2 cases and ganglioneuroma in 2 cases.
  • Delivery of the tumor was done in 8 cases, widening of the intervertebral foramina in 3 cases, costotransversectomy with lateral laminectomy in 3 cases while posterior laminectomy and total vertebrectomy was done in one case.
  • We fixed the spine in 3 cases using Z-plate and screws, lateral plates and screws with either iliac crest or isobone graft.
  • C-T guided biopsy can select patients with pathological diagnosis that could be sensitive to pre operative chemotherapy and/or radiotherapy to facilitate surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601967.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


3. Stefanowicz J, Izycka-Swieszewska E, Drozyńska E, Pienczk J, Połczyńska K, Czauderna P, Sierota D, Bień E, Stachowicz-Stencel T, Kosiak W, Balcerska A: Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome--clinical and pathological characteristics. Folia Neuropathol; 2008;46(3):176-85
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two of the children the onset of neurological symptoms was connected with a vaccination and in one with viral infection.
  • All cases were in stage II or III of the disease, with no metastases or MYCN amplification.
  • The group included two ganglioneuroblastomas, one ganglioneuroma and one differentiating neuroblastoma.
  • Immunohistochemical analysis of inflammatory infiltrations revealed mixed type populations of lymphocytes with prevalence of the cytotoxic type (CD8 and CD56-positive cells).
  • All patients were treated by surgery alone or with adjuvant chemotherapy with a positive outcome.


Advertisement
4. Miyauchi J, Kiyotani C, Shioda Y, Kumagai M, Honna T, Matsuoka K, Masaki H, Aiba M, Hata J, Tsunematsu Y: Unusual chromaffin cell differentiation of a neuroblastoma after chemotherapy and radiotherapy: report of an autopsy case with immunohistochemical evaluations. Am J Surg Pathol; 2004 Apr;28(4):548-53
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual chromaffin cell differentiation of a neuroblastoma after chemotherapy and radiotherapy: report of an autopsy case with immunohistochemical evaluations.
  • Neuroblastomas are derived from neural crest cells that are capable of multilineage differentiation.
  • Ganglionic neuronal differentiation of childhood neuroblastoma is seen with increasing age, leading to more differentiated tumors called ganglioneuroblastomas or ganglioneuromas.
  • Tumor cells with a chromaffin-cell nature have only been detected using histochemical techniques in neuroblastoma cell lines or focal areas of certain in vivo tumors.
  • We describe a neuroblastoma that exhibited an unusual differentiation toward chromaffin cells in a patient that had been treated with surgery, intensive chemotherapy, and radiotherapy.
  • Although a biopsy specimen of the retroperitoneal primary tumor was extensively necrotic, possibly because of a previous chemotherapy regimen, surgically resected metastatic tumors of bilateral ovaries were viable and diagnosed as poorly differentiated neuroblastomas according to the International Neuroblastoma Pathology Classification system.
  • However, metastatic tumors of bilateral lungs examined at the time of autopsy exhibited histologic features similar to those of a pheochromocytoma/paraganglioma, and immunohistochemical examinations demonstrated that these tumors were composed of extra-adrenal chromaffin cells.
  • [MeSH-minor] Cell Differentiation. Child, Preschool. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15087676.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Kitauchi T, Kagebayashi Y, Hosokawa Y, Otani T, Yoshida K, Ohzono S, Hirao Y, Matsumoto K, Okumura H: [A case of long-term survival neuroblastoma with conservative therapy]. Hinyokika Kiyo; 2002 Feb;48(2):71-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival neuroblastoma with conservative therapy].
  • We report a case of long-term survival in a patient with neuroblastoma treated with conservative therapy.
  • A 2-year-old female patient who presented with a lower abdominal mass was diagnosed with neuroblastoma.
  • Resection of the tumor was not successful because of adhesion.
  • Postoperatively 50 Gy-radiation and chemotherapy were performed.
  • At age 17, needle biopsy of the tumor was performed, and the histopathological diagnosis was ganglioneuroma.
  • [MeSH-major] Abdominal Neoplasms / therapy. Neuroblastoma / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Female. Ganglioneuroblastoma / pathology. Humans. Hydronephrosis / complications. Hydronephrosis / surgery. Survivors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968730.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Berthold F, Hero B: Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs; 2000 Jun;59(6):1261-77
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma: current drug therapy recommendations as part of the total treatment approach.
  • Neuroblastoma represents one of the most challenging malignancies for treatment decisions because of its unusual biological behaviour.
  • The features include spontaneous regression (regressive type), maturation to ganglioneuroma (maturative type) and largely treatment-resistant progression (progressive type).
  • Current knowledge allows only partial prediction of type.
  • For practical reasons, patients may be categorised as an 'observation', a 'standard risk' or a 'high risk' treatment arm.
  • The main achievements were the reduction of chemotherapy in patients with localised disease and the increased efficacy of chemotherapy in metastatic neuroblastoma stage 4 (5-year survival increased from 8 to 33%).
  • Different goals for chemotherapy (e.g. stopping rapid progression, improvement of symptoms, induction and maintenance of remission) require different dosages and durations of treatment (range 1 week to 9 months).
  • The main risks of chemotherapy are toxic death (rate up to 15%) predominantly during the periods of bone marrow depression and the development of secondary leukaemias (up to 7% cumulative risk after 4 years).
  • In conclusion, the use of cytotoxic drugs can be completely omitted in a substantial proportion of low risk patients with neuroblastoma.
  • On the other hand, for high risk patients with the disease, intensive polychemotherapy represents the basis and the backbone of treatment among other modalities.
  • [MeSH-major] Neuroblastoma / drug therapy
  • [MeSH-minor] Drug Resistance, Neoplasm. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Dec 21-28;348(9043):1682-7 [8973429.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3286-94 [9779703.001]
  • [Cites] Br J Cancer. 1982 Jan;45(1):86-94 [7037033.001]
  • [Cites] Med Pediatr Oncol. 1995 Apr;24(4):215-21 [7700165.001]
  • [Cites] Nat Med. 1995 Mar;1(3):249-55 [7585042.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2101-5 [9516862.001]
  • [Cites] Am J Hum Genet. 1994 Aug;55(2):334-40 [8037210.001]
  • [Cites] N Engl J Med. 1993 Mar 25;328(12):847-54 [8441429.001]
  • [Cites] J Neuroimmunol. 1999 May 3;96(2):201-6 [10337918.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):305-15 [1678252.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3880-9 [9850034.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5366-9 [7585602.001]
  • [Cites] Exp Hematol. 1997 Nov;25(12):1253-60 [9357969.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):945-52 [9508177.001]
  • [Cites] Lancet. 1998 Aug 29;352(9129):682-7 [9728983.001]
  • [Cites] Br J Cancer. 1986 Nov;54(5):771-8 [3542005.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):353-9 [10219337.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1009-14 [9818076.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2126-9 [9516867.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):231-8 [8532000.001]
  • [Cites] Br J Cancer. 1988 Jan;57(1):121-6 [3348945.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):581-91 [2066755.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):1050-8 [2033419.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1063-9 [9849455.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2044-50 [8481906.001]
  • [Cites] N Engl J Med. 1985 Oct 31;313(18):1111-6 [4047115.001]
  • [Cites] N Engl J Med. 1996 Jun 6;334(23):1505-11 [8618605.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(5):411-8 [1595194.001]
  • [Cites] Eur J Cancer. 1995;31A(4):616-21 [7576981.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):236-44 [2915240.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):741-9 [10091748.001]
  • [Cites] Biol Rev Camb Philos Soc. 1975 May;50(2):129-65 [240451.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2092-7 [9516860.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):220-3 [11464889.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5396-405 [9850071.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2130-5 [9516868.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1994 May;16(2):107-15 [8166363.001]
  • [Cites] J Hematother. 1997 Jun;6(3):235-42 [9234178.001]
  • [Cites] Cell Death Differ. 1994;1(2):123-8 [17180025.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):468-76 [10653862.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2504-10 [8823329.001]
  • [Cites] Klin Padiatr. 1990 Jul-Aug;202(4):262-9 [2203940.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):225-30 [8531999.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3823-9 [9288794.001]
  • (PMID = 10882162.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 56
  •  go-up   go-down


7. Chen PY, Chen WY, Ho DM, Pan CC: Malignant ganglioneuroma arising from mediastinal mixed germ cell tumor. J Chin Med Assoc; 2007 Feb;70(2):76-9
Genetic Alliance. consumer health - Malignant germ cell tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ganglioneuroma arising from mediastinal mixed germ cell tumor.
  • Mixed germ cell tumor was initially diagnosed based on the pathologic findings of germinoma on thoracoscopic biopsy and clinical findings of elevated serum alpha-fetoprotein and beta-human chorionic gonadotropin.
  • The patient received preoperative chemotherapy and subsequent complete resection of the residual tumor.
  • Pathologic examination of the excised specimen showed predominantly malignant ganglioneuroma and small residual foci of teratoma.
  • To our knowledge, this is the first reported case of a malignant ganglioneuroma arising from mediastinal mixed germ cell tumor.
  • [MeSH-major] Ganglioneuroma / etiology. Mediastinal Neoplasms / complications. Neoplasms, Germ Cell and Embryonal / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339149.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL: Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab; 2006 Dec;91(12):4776-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypothalamic gangliocytomas producing GHRH are also known to be associated with pituitary adenomas causing acromegaly.
  • SUBJECT: The patient was a 44-yr-old woman who was diagnosed with a biopsy-proven metastatic pulmonary endocrine tumor during pregnancy.
  • After delivery, she underwent radiation and chemotherapy for pulmonary and skeletal metastases.
  • Her disease was clinically stable for 7 yr until she developed bitemporal hemianopia.
  • The patient underwent uneventful transsphenoidal resection of the sellar tumor.
  • Histological examination confirmed metastatic endocrine carcinoma to the pituitary, and immunohistochemistry localized GHRH to the tumor cells.
  • CONCLUSION: This is the first report of a GHRH-producing endocrine tumor metastasizing to the pituitary and causing local hyperstimulation with somatotroph hyperplasia and adenomatous transformation.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968791.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones, Ectopic; 0 / Indium Radioisotopes; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


9. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL: Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics; 2002 Jul-Aug;22(4):911-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation.
  • Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma are tumors of the sympathetic nervous system that arise from primitive sympathogonia and are referred to collectively as neuroblastic tumors.
  • They arise wherever sympathetic tissue exists and may be seen in the neck, posterior mediastinum, adrenal gland, retroperitoneum, and pelvis.
  • The three tumors differ in their degree of cellular and extracellular maturation; immature tumors tend to be aggressive and occur in younger patients (median age, just under 2 years), whereas mature tumors occur in older children (median age, approximately 7 years) and tend to behave in a benign fashion.
  • The most benign tumor is the ganglioneuroma, which is composed of gangliocytes and mature stroma.
  • Neuroblastoma is the most immature, undifferentiated, and malignant tumor of the three.
  • Neuroblastoma, however, may have a relatively benign course, even when metastatic.
  • Features such as DNA content, tumor proto-oncogenes, and catecholamine synthesis influence prognosis, and their presence or absence aids in categorizing patients as high, intermediate, or low risk.
  • Treatment consists of surgery and, usually, chemotherapy.
  • Despite recent advances in treatment, including bone marrow transplantation, neuroblastoma remains a relatively lethal tumor, accounting for 10% of pediatric cancers but 15% of cancer deaths in children.
  • [MeSH-major] Ganglioneuroma / pathology. Ganglioneuroma / radiography. Neuroblastoma / pathology. Neuroblastoma / radiography
  • [MeSH-minor] Ganglioneuroblastoma / pathology. Ganglioneuroblastoma / radiography. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Prognosis. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2002
  • (PMID = 12110723.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


10. De Moerloose B: [The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma]. Verh K Acad Geneeskd Belg; 2005;67(1):45-54
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • P-glycoprotein (P-gp), a pump located in the cell membrane, extrudes several clinically important drugs from the cell, and hence causes multidrug resistance (MDR).
  • Children scoring positive had a significantly worse outcome than those with a negative test result.
  • In neuroblastoma, ganglioneuroblastoma and ganglioneuroma, P-gp is detected by different assays: immunocytochemistry, flow cytometric immunological and functional tests and an in vivo imaging technique using 99mTc sestamibi.
  • P-gp was found more frequently in low-stage neuroblastoma, differentiated tumours and tumours after chemotherapy.
  • [MeSH-major] Neuroblastoma / drug therapy. P-Glycoprotein / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm. Flow Cytometry. Humans. Immunohistochemistry / methods. Predictive Value of Tests. Prognosis. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15828306.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / P-Glycoprotein
  • [Number-of-references] 19
  •  go-up   go-down


11. Pérel Y, Valteau-Couanet D, Michon J, Lavrand F, Coze C, Bergeron C, Notz A, Plantaz D, Chastagner P, Bernard F, Thomas C, Rubie H: [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use]. Arch Pediatr; 2004 Jul;11(7):834-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma and its benign counterpart, ganglioneuroma, are pediatric neuroblastic tumors arising in the sympathetic nervous system from neural-crest cells.
  • Neuroblastoma, the most common extra-cranial solid tumour during childhood, is unique for its broad spectrum of clinical virulence from spontaneous remission to rapid and fatal progression despite intensive multimodality therapy.
  • To a large extent, outcome could be predicted by the stage of disease and the age at diagnosis.
  • However, a number of molecular events in neuroblastoma tumors, accounting for the variability of outcome and response to therapy, have been identified over the past decades.
  • Among these, MYCN amplification is the most relevant prognostic factor and was the first genetic marker, in paediatric oncology, to be included in clinical strategies as a guide for therapeutic decision.
  • This has allowed the most suitable intensity of therapy to be delivered according to a risk-stratified strategy, from observation to megadose chemotherapy with stem cell transplantation.
  • Recent advances in understanding the biology and genetics of neuroblastoma will ultimately allow to select poor-risk patients for appropriate future biologically based therapies.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Patient Selection. Prognosis. Risk Factors. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234382.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 71
  •  go-up   go-down


12. Chen KS, Hung PC, Wang HS, Jung SM, Ng SH: Medulloblastoma or cerebellar dysplastic gangliocytoma (Lhermitte-Duclos disease)? Pediatr Neurol; 2002 Nov;27(5):404-6
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma or cerebellar dysplastic gangliocytoma (Lhermitte-Duclos disease)?
  • Dysplastic cerebellar gangliocytoma is a rare benign tumor associated with specific neuroimaging findings of abnormal laminated or folial pattern in the posterior fossa.
  • We encountered a patient with medulloblastoma in which the neuroimaging findings mimicked those of dysplastic gangliocytoma.
  • In patients with a posterior fossa tumor suggestive of a dysplastic gangliocytoma on neuroimaging studies, a pathologic confirmation is necessary.
  • [MeSH-major] Cerebellum / pathology. Ganglioneuroma / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Drug Therapy. Gadolinium. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm, Residual / surgery. Reoperation. Tomography, X-Ray Computed


13. Lam CH, Nagib MG: Nonteratomatous tumors in the pediatric sacral region. Spine (Phila Pa 1976); 2002 Jun 1;27(11):E284-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other common benign congenital tumors of the sacrum include lipomas, dermoids, and epidermoids.
  • One patient underwent a posterior resection and will undergo a second stage anterior approach later to allow for chemotherapy and radiation to shrink the intrapelvic portion of the tumor.
  • They included ganglioneuroma (n = 1), myxopapillary ependymoma (n = 2), primitive neuroectodermal tumor (n = 1), aneurysmal bone cyst (n = 1), and Ewing's sarcoma (n = 1).
  • No progression of disease has occurred in the follow-up period of 1.5 to 7 years (average, 5 years).
  • Multiple therapeutic methods may be required, including adjuvant chemotherapy and, possibly, embolization.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Ependymoma / diagnosis. Ganglioneuroma / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Back Pain / etiology. Child. Coccyx / pathology. Constipation / etiology. Female. Gait Disorders, Neurologic / etiology. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Male. Retrospective Studies. Sacrococcygeal Region. Sacrum / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12045531.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


14. Lara-Bohórquez C, González-Cámpora R, Mendoza-García E, Ríos-Martín JJ, Pareja-Megía MJ, López-Beltrán A: TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors. Anal Quant Cytol Histol; 2008 Apr;30(2):105-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors.
  • OBJECTIVE: To identify markers of response to therapy in neuroblastic tumors.
  • STUDY DESIGN: A total of 58 patients with neuroblastic tumor (38 neuroblastomas, 13 ganglioneuroblastomas and 7 ganglioneuromas) were included in the study.
  • TP53, BCL-2, p21Waf1/Cip1 and metallothionein were included as a biologic approach to tumor differentiation, response to therapy and prognosis.
  • RESULTS: Patients who died of disease had the following immunophenotype: BCL-2 (9 of 10), nuclear TP53 (7 of 10) and metallothionein (7 of 10).
  • TP-53 expression was related to clinical stage (p = 0.062) and disease outcome (p = 0.0218).
  • All patients in whom treatment failed expressed metallothionein (3 of 3).
  • CONCLUSION: TP53, BCL-2, p21Waf1/Cip1 and metallothionein had limited value reflecting tumor maturation (differentiation) or predicting response to therapy.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561747.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


15. Duhem-Tonnelle V, Vinchon M, Defachelles AS, Cotten A, Dhellemmes P: Mature neuroblastic tumors with spinal cord compression: report of five pediatric cases. Childs Nerv Syst; 2006 May;22(5):500-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas neuroblastomas (NB) are relatively common and are generally treated with chemotherapy, mature neuroblastic tumors (MNT), which include intermixed ganglioneuroblastomas (iGNB) and ganglioneuromas (GN), are less common and the role of surgery is more prominent.
  • The neurological and oncological outcomes were generally favorable after surgical resection, followed by orthotic treatment.
  • In one case with neurofibromatosis type 1, the tumor was inoperable and the child died of tumor progression several years later.
  • Surgery is an emergency in case of rapidly progressing paraplegia and can be challenging because the tumor is often hard and hemorrhagic.
  • In case of subtotal removal, tumor remnants can stay stable without oncological treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Nurs Mirror Midwives J. 1975 Nov 6;141(19):48-52 [1042886.001]
  • [Cites] Cancer. 2001 May 15;91(10 ):1905-13 [11346873.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):311-9 [8674009.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):215-20 [1574031.001]
  • [Cites] Pediatr Neurosurg. 2003 Dec;39(6):291-8 [14734862.001]
  • [Cites] J Child Neurol. 1998 Jul;13(7):356-8 [9701489.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):353-9 [10219337.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):579-83 [12948463.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1211-4 [2917322.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1837-40 [4027922.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4 Suppl):875-7 [7611061.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1047-55 [11181668.001]
  • (PMID = 16369850.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Das DK, Sarin YK, Grover RK, Jain J, Khan VA, Chachra KL, Chowdhury V: Neuroblastoma with concomitant giardiasis: report of a case with diagnosis by fine needle aspiration cytology. Acta Cytol; 2001 Sep-Oct;45(5):740-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Repeat smears showed a small round cell tumor with rosettes and background filamentous/fibrillar material consistent with a neuroblastoma.
  • Chemotherapy reduced the mass considerably.
  • Histopathology of the resected residual mass revealed a ganglioneuroma in addition to remnants of neuroblastoma.
  • The patient was free of disease two years after the initiation of chemotherapy.
  • CONCLUSION: When FNA cytology shows an infectious pathology in the clinical and imaging setting of a tumor, FNA should be repeated so that an important component of the diagnosis is not missed.


17. DeCou JM, Schlatter MG, Mitchell DS, Abrams RS: Primary thoracoscopic gross total resection of neuroblastoma. J Laparoendosc Adv Surg Tech A; 2005 Oct;15(5):470-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our purpose was to study the safety and efficacy of thoracoscopic resection and to evaluate tumor data and patient outcomes.
  • Data included demographics, symptoms, size, location, operative time, complications, hospital stay, histology, biologic markers, adjuvant therapy, and outcome.
  • Tumor size ranged from 2.1 to 6.0 cm.
  • Operative time ranged from 64 to 175 minutes.
  • The only complications were two cases of small tumor spillage.
  • Histology ranged from ganglioneuroma to differentiating NB, with a favorable classification in 4 of 5 cases.
  • Chemotherapy or radiation therapy was not indicated for any patient.
  • All are alive with no evidence of disease at 14 to 55 months' follow-up.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185118.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Batra YK, Rajeev S, Rao KL: Anesthesia management of a ganglioneuroma with seizures presenting as pheochromocytoma. Paediatr Anaesth; 2007 May;17(5):479-83
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anesthesia management of a ganglioneuroma with seizures presenting as pheochromocytoma.
  • Ganglioneuromas (GN) are neural crest cell-derived tumors which may coexist with pheochromocytomas, secrete various neuropeptides or the symptoms may mimic that of a pheochromocytoma, producing hypertension or a hypotensive crisis during anesthesia for these tumors.
  • We report here the case of a 7-year-old female child with an adrenal tumor suspected to be a pheochromocytoma, later confirmed by histology as a GN.
  • This child presented with episodic headache, anxiety, palpitations and 3D helical (spiral) computed tomography of the abdomen revealed an adrenal tumor.
  • Although the child's preoperative catecholamine levels were normal, tumor manipulation caused a hypertensive crisis.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Anesthesia / methods. Epilepsy / complications. Ganglioneuroma / diagnosis. Pheochromocytoma / diagnosis
  • [MeSH-minor] Anesthesia, Epidural / methods. Anesthetics, Inhalation / administration & dosage. Anesthetics, Intravenous / administration & dosage. Anesthetics, Local / administration & dosage. Antihypertensive Agents / administration & dosage. Anxiety / etiology. Blood Pressure / drug effects. Central Venous Pressure / drug effects. Child. Diagnosis, Differential. Female. Headache / etiology. Heart Rate / drug effects. Humans. Hypertension / drug therapy. Hypertension / etiology. Neuromuscular Nondepolarizing Agents / administration & dosage. Radiography, Abdominal / methods. Rare Diseases. Tomography, Spiral Computed / methods

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Anesthesia.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474956.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; 0 / Anesthetics, Intravenous; 0 / Anesthetics, Local; 0 / Antihypertensive Agents; 0 / Neuromuscular Nondepolarizing Agents
  •  go-up   go-down


19. Castellani MR, Chiti A, Seregni E, Bombardieri E: Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med; 2000 Mar;44(1):77-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
  • BACKGROUND: 45 patients with neuroendocrine tumours (22 neuroblastomas, 10 phaeochromocytomas, 3 para-gangliomas, 6 medullary thyroid carcinomas and 4 carcinoids) underwent 131I-MIBG therapy.
  • METHODS: All patients, with the exception of 5 phaeochromocytoma cases with nonoperable disease, had previously been treated with conventional therapies.
  • The therapeutic activity for adults ranged from 3.7 to 7.4 GBq of 131I-MIBG; for children from 2.7 to 5.5 GBq.
  • All treatments were repeated at not less than 4-weekly intervals.
  • The neuroblastoma patients were divided into two groups: the first included 14 patients with advanced metastatic disease not responding to previous treatments; the second included 8 patients with documented residual neuroblastoma tissue that could not be surgically removed after first-line therapy.
  • RESULTS: In neuroblastoma patients with advanced disease resistant to previous therapies 2 out of 14 showed a partial response, 9 stable disease and 3 progression of cancer.
  • In neuroblastoma patients with residual disease (7 evaluable out of 8) we obtained 3 partial responses; a stable response was observed in 3 patients.
  • The results of MIBG therapy in the group of phaeochromocytoma patients (9 evaluable out of 10) consisted of 3 partial responses, 5 stable disease and 1 progression.
  • Evaluation of the response carried out on the basis of biochemical parameters increased the responses and MIBG therapy showed good effectiveness in controlling the functional symptoms.
  • In patients with medullary thyroid carcinoma a partial response was observed in 1 patient with mediastinal metastases and 2 disease stabilisations were seen in another 2 patients.
  • Patients with carcinoids who underwent MIBG therapy showed 3 disease stabilisations.
  • The overall toxicity was acceptable, especially considering that the majority of our patients had had previous myelotoxic treatments (chemotherapy and/or radiotherapy, alone or in combination).
  • CONCLUSIONS: On the basis of our experience we can conclude that 131I-MIBG therapy is effective and also well tolerated.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Neuroendocrine Tumors / radiotherapy. Radiopharmaceuticals / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10932604.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


20. Jeibmann A, Hasselblatt M, Pfister S, Sträter R, Brentrup A, Holling M, Niederstadt T, Paulus W, Frühwald MC: From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior. J Neurosurg Pediatr; 2009 Nov;4(5):475-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior.
  • Few GBMs in children, however, seem to respond quite well to adjuvant chemotherapy.
  • The biological basis for such chemotherapy sensitivity remains uncertain.
  • In this paper the authors report the case of a 2-month-old girl with a histologically confirmed GBM (WHO Grade IV) in whom chemotherapy was accompanied by differentiation of the malignant primary tumor into a typical gangliocytoma (WHO Grade I) showing ganglioid differentiation and expression of neuronal markers synaptophysin, neurofilament, and NeuN as well as a low Ki 67/MIB-1 proliferation index.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Ganglioneuroma / pathology. Ganglioneuroma / therapy. Glioblastoma / pathology. Glioblastoma / therapy
  • [MeSH-minor] Antigens, Nuclear / metabolism. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Carboplatin / administration & dosage. Cell Differentiation. Cell Proliferation. Etoposide / administration & dosage. Female. Humans. Hydrocephalus / pathology. Infant. Nerve Tissue Proteins / metabolism. Neurofilament Proteins / metabolism. Neurosurgical Procedures. Reverse Transcriptase Polymerase Chain Reaction. Synaptophysin / metabolism

  • Genetic Alliance. consumer health - Gangliocytoma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19877783.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Synaptophysin; 0 / neuronal nuclear antigen NeuN, human; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


21. Matyja G, Dziekan T, Dobrzycki W: [Rare neck tumors: diagnosis and treatment]. Otolaryngol Pol; 2000;54 Suppl 31:87-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare neck tumors: diagnosis and treatment].
  • Among them were: paraganglioma--3 cases, neurilemmoma--3 cases, actinomycosis--2 cases and 1 case of plasmocytoma, ganglioneuroma, oncocytoma, lipoma, toxoplasmosis and cystic tumour of salivary gland origin.
  • Beside surgery antibiotics, chemotherapy and RTG therapy were applied, depending on the kind of the tumour.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974852.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


22. Floris G, Debiec-Rychter M, Wozniak A, Magrini E, Manfioletti G, De Wever I, Tallini G, Sciot R: Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation. Diagn Mol Pathol; 2007 Dec;16(4):243-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant ectomesenchymoma (MEM) represents a heterogeneous group of tumors, most likely originating from pluripotent primitive neural crest cells.
  • Retrospective review of the incision biopsy showed the presence of a few ganglion cells in an otherwise classic embryonal rhabdomyosarcoma (RMS), whereas in the resection specimen after chemotherapy the combined RMS and ganglioneuroma components were very obvious.
  • Cytogenetic analysis of the residual lesion showed an abnormal karyotype, 49, XY, +2, -6, +11, +20, +mar, with a hyperploidy in a subset of cells.
  • By fluorescence in situ hybridization analysis, the marker chromosome was identified as originating from chromosome 6, and the tumor cells were negative for PAX3/PAX7 disrupting translocations specific for alveolar RMS.
  • Gains of chromosomes 2, 11, and 20, found in the current case, are a common finding in embryonal RMS.
  • The genomic profiles of both specimens were basically the same including the presence of 2 distinctive chromosome 6p21.32-p21.2 and 6p11.2 amplification regions in the primary tumor, which vanished in the postchemotherapy specimen.
  • The pretreatment biopsy exhibited strong expression of HMGA1 and HMGA2 proteins in immunohistochemistry, with the shift toward the loss of expression of both genes in the posttreatment tumoral tissue.
  • This finding supports the oncogenic properties of the HMGA family of proteins and their role in the process of malignant transformation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043289.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors; 124544-67-8 / HMGA1a Protein
  •  go-up   go-down


23. Luis AL, Martínez L, Hernández F, Sastre A, García P, Queizán A, Tovar JA: [Congenital neuroblastomas]. Cir Pediatr; 2004 Apr;17(2):89-92
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present herein our experience in the treatment of this condition and we try to find out any different clinical pattern from those neuroblastomas diagnosed later in life.
  • METHODS: We review the CN treated in our hospital from 1990 to 2003, analyzing diagnosis, localization, tumor staging, N-myc amplification, treatment and evolution.
  • RESULTS: Among the 107 neural tumors managed during this period (89 neuroblastomas, 18 ganglioneuromas), 8 were congenital neuroblastomas (7 girls, 1 boy).
  • Although most of them had unfavorable histology, we didn't find N-myc amplification in any tumor.
  • All patients were operated upon, with preoperative chemotherapy in 2 of them.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285592.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Moran C, Greiner RJ, Mardam-Bey SW 3rd, Hollingsworth CL, Kulbacki E, Wechsler DS: Synchronous occurrence of metastatic Wilms tumor and ganglioneuroma. Pediatr Blood Cancer; 2010 Sep;55(3):562-5
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of metastatic Wilms tumor and ganglioneuroma.
  • We describe a 4-year-old female patient with a persistent paraspinal mass following chemotherapy for Wilms tumor.
  • A discordant response to chemotherapy prompted biopsy of the persistent mass, which revealed a ganglioneuroma.
  • This report highlights the synchronous occurrence of different tumors in the same patient, and suggests that repeat biopsies should be considered when contiguous tumor masses do not respond as expected.
  • [MeSH-major] Ganglioneuroma / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Spinal Neoplasms / pathology. Wilms Tumor / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658632.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043494
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, Schmid I, Hahn K: Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol; 2003 Oct;181(4):1115-24
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objectives of this study were to compare MRI and iodine-123 ((123)I) metaiodobenzylguanidine (MIBG) scintigraphy in the detection of neuroblastoma lesions in pediatric patients and to assess the additional value of combined imaging.
  • On MRI, 15 false-positive findings were recorded: posttherapeutic reactive changes (n = 10), benign adrenal tumors (n = 3), and enlarged lymph nodes (n = 2).
  • On MIBG scintigraphy, 10 false-positive findings occurred: ganglioneuromas (n = 2), benign liver tumors (n = 2), and physiologic uptake (n = 6).
  • Thirteen neuroblastoma metastases and two residual masses under treatment with chemotherapy were judged to be false-negative findings on MRI.
  • Two primary or residual neuroblastomas and one orbital metastasis were misinterpreted as Wilms' tumor, reactive changes after surgery, and rhabdomyosarcoma on MRI.
  • On combined imaging, one false-negative (bone metastasis) and three false-positive (two ganglioneuromas and one pheochromocytoma) findings remained.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14500242.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodobenzenes; 14629-13-1 / 4-iodobenzylguanidine
  •  go-up   go-down


26. Chelliah D, Mensah Sarfo-Poku C, Stea BD, Gardetto J, Zumwalt J: Medulloblastoma with extensive nodularity undergoing post-therapeutic maturation to a gangliocytoma: a case report and literature review. Pediatr Neurosurg; 2010;46(5):381-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gangliocytoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma with extensive nodularity undergoing post-therapeutic maturation to a gangliocytoma: a case report and literature review.
  • A gross total resection was performed followed by adjuvant systemic chemotherapy due to his young age; however, the tumor recurred locally in the posterior fossa 7 months later.
  • The recurrent tumor was excised and he received craniospinal radiation with a boost given to the posterior fossa followed by high-dose chemotherapy.
  • He remained disease free for approximately 10 years without major neurologic deficit and only mild cognitive impairment.
  • The patient underwent surgical debulking and pathological examination revealed no residual immature medulloblastoma cells but instead mature ganglion cells, consistent with a gangliocytoma.
  • The apparent maturation of primitive medulloblastoma cells is a rare phenomenon, which may have ensued from the long-term effects of adjuvant therapies inducing advanced cellular maturation.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Ganglioneuroma / surgery. Medulloblastoma / surgery. Neoplasm Recurrence, Local / surgery

  • Genetic Alliance. consumer health - Gangliocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389751.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


27. De Bernardi B, Gambini C, Haupt R, Granata C, Rizzo A, Conte M, Tonini GP, Bianchi M, Giuliano M, Luksch R, Prete A, Viscardi E, Garaventa A, Sementa AR, Bruzzi P, Angelini P: Retrospective study of childhood ganglioneuroma. J Clin Oncol; 2008 Apr 1;26(10):1710-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of childhood ganglioneuroma.
  • PURPOSE: To review a historical cohort of childhood ganglioneuroma (GN), the benign representative of the peripheral neuroblastic tumor (PNT) family.
  • RESULTS: GNs differed from other PNTs for sex, age, tumor site, stage, tumor markers, and scintigraphic results.
  • Radical tumor resection and surgery-related complication rates were comparable for GN, GNBI, and nonreviewed instances.
  • Six patients developed tumor progression but survived.
  • Two patients developed a late malignancy but survived.
  • None of the 146 patients received chemotherapy.
  • Survival was not influenced by extent of tumor resection.
  • [MeSH-major] Ganglioneuroma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Miyake M, Tateishi U, Maeda T, Arai Y, Seki K, Hasegawa T, Sugimura K: A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med; 2006 Jun;20(5):357-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ganglioneuroma presenting abnormal FDG uptake.
  • We report a case of ganglioneuroma with abnormal 18F-fluorodeoxyglucose (FDG) uptake.
  • A 26-year-old woman presented to the hospital with a slowly growing abdominal tumor without symptoms.
  • She was diagnosed with neuroblastoma in childhood and treated by surgery and chemotherapy.
  • Computed tomography (CT) revealed huge retroperitoneal tumors and fused 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT image showed abnormal accumulation of FDG in tumors with maximal standardized uptake value of 2.02.
  • Considering her past history, ganglioneuroma matured from neuroblastoma was considered, the most likely diagnosis.
  • However, a second primary malignant tumor, such as malignant peripheral nerve sheath tumor arising in ganglioneuroma, could not be ruled out.
  • Then, an excisional biopsy was performed and the diagnosis of mature ganglioneuroma was made.
  • Pathological investigation may be needed to differentiate ganglioneuroma from other malignant tumors and, therefore, FDG-PET/CT findings can be helpful for biopsy planning.
  • [MeSH-major] Abdominal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neuroma / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878708.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Ito T, Imai T, Kikumori T, Shibata A, Horiba T, Kobayashi H, Sawaki M, Watanabe R, Nakao A, Kiuchi T: Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today; 2006;36(11):961-5
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result.
  • METHODS: We defined adrenal incidentaloma as a tumor detected during abdominal imaging for adrenal-unrelated reasons, and we reviewed 197 consecutive patients with adrenal incidentaloma diagnosed since we started laparoscopic adrenalectomy.
  • Laparoscopic right adrenalectomy resulted in a pathological diagnosis of ganglioneuroma.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / urine. Biomarkers, Tumor / urine. Mesalamine / pharmacokinetics. Normetanephrine / urine. Pheochromocytoma / diagnosis. Pheochromocytoma / urine
  • [MeSH-minor] Adrenalectomy / methods. Adult. Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Colitis, Ulcerative / drug therapy. Colitis, Ulcerative / urine. Diagnosis, Differential. False Positive Reactions. Female. Humans. Incidence. Laparoscopy. Male. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5130-7 [11701665.001]
  • [Cites] Clin Chem. 1999 Dec;45(12):2216-23 [10585355.001]
  • [Cites] Clin Chem. 2001 Jun;47(6):1061-7 [11375292.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] Asian J Surg. 2003 Apr;26(2):64-70 [12732488.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):50-3; discussion 54 [10456703.001]
  • [Cites] N Engl J Med. 1995 Feb 9;332(6):401 [7824012.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66 [12788870.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:120s-125s [12487267.001]
  • [Cites] Ann Clin Biochem. 1984 Sep;21 ( Pt 5):446 [6508218.001]
  • [Cites] Surg Endosc. 1999 Apr;13(4):343-5 [10094744.001]
  • [Cites] Biomed Pharmacother. 2000 Jun;54 Suppl 1:140s-145s [10915011.001]
  • [Cites] World J Surg. 2001 Jul;25(7):905-13 [11572032.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):85-91 [11420487.001]
  • [Cites] World J Surg. 1998 Jul;22(7):684-8 [9606282.001]
  • (PMID = 17072715.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor; 0J45DE6B88 / Normetanephrine; 4Q81I59GXC / Mesalamine
  •  go-up   go-down


30. Kim DH, Murovic JA, Tiel RL, Kline DG: Operative outcomes of 546 Louisiana State University Health Sciences Center peripheral nerve tumors. Neurosurg Clin N Am; 2004 Apr;15(2):177-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surgical management of benign PNSTs and some other benign tumors can result in successful outcomes.
  • Schwannomas and nonplexiform neurofibromas can be resected with minimal deficit by sparing all but the fascicles entering and exiting the tumor.
  • These fascicles, if not functional by NAP testing, can be resected, and the tumor can be removed.
  • Surgery to remove other benign lesions, such as intraneural ganglion cysts, hemangiomas,and ganglioneuromas, has become more timely.
  • The desmoid tumor, although microscopically benign, is locally and regionally invasive, and chemotherapy and radiation therapy may need to be used as adjunctive therapy.
  • Neurogenic sarcomas and other malignancies have high morbidity and mortality despite aggressive limb ablation or limb-sparing surgery with adjunctive therapy.
  • [MeSH-minor] Academic Medical Centers. Humans. Louisiana. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15177317.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


31. Miura K, Mineta H, Yokota N, Tsutsui Y: Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy. Pathol Int; 2001 Dec;51(12):942-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy.
  • We report a 56-year-old man in whom an olfactory neuroblastoma with epithelial and endocrine differentiation transformed into a mature ganglioneuroma after chemoradiotherapy.
  • The tumor arising from the sphenoidal and maxillary sinuses showed rapid growth into the frontal lobe and metastasis to the cervical lymph nodes.
  • A radical craniofacial resection of the primary tumor was performed after 16 Gy of local irradiation and systemic chemotherapy.
  • After chemoradiotherapy, the histology changed to that of a ganglioneuroma consisting of large ganglion cells and Schwann cells without immature neuroblastoma components.
  • Although transformation to ganglioneuroma in an adrenal neuroblastoma is common, an olfactory neuroblastoma showing ganglioneuronal maturation after chemoradiotherapy has not been reported.
  • [MeSH-major] Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / radiation effects. Esthesioneuroblastoma, Olfactory / pathology. Ganglioneuroma / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Humans. Inappropriate ADH Syndrome. Male. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11844067.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


32. Tahri A, Benchekroun N, Karkouri M, Dahami Z, Sahraoui S, Acharki A, Benider A, Squalli S, Benjelloun S, Kahlain A: [Nephroblastoma in adults. Three case reports]. Ann Urol (Paris); 2001 Sep;35(5):257-61
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At diagnosis, radiological exams revealed that patients presented an advanced stage and metastatic disease in one case.
  • The treatment was a total nephrectomy with ganglioma dissection when the tumor was resectable followed by chemotherapy and radiotherapy.
  • Two patients was in progressive disease despite treatment, and one patient was lost at follow-up.
  • The prognosis of adult's nephroblastoma remains very severe, due to the advanced stage at diagnosis and the mediocre reply to the treatment.
  • [MeSH-major] Kidney Neoplasms / pathology. Nephrectomy. Wilms Tumor / pathology
  • [MeSH-minor] Adult. Age of Onset. Chemotherapy, Adjuvant. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11675960.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Wang H, Zhang JH, Mi Z: [Neuronal differentiation and TrkA expression of neuroblastoma induced by the combination treatment of interferon-gamma and NGF]. Zhonghua Er Ke Za Zhi; 2004 Mar;42(3):180-3
Genetic Alliance. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuronal differentiation and TrkA expression of neuroblastoma induced by the combination treatment of interferon-gamma and NGF].
  • A small percentage of NB has been found to undergo spontaneous or chemotherapeutically induced regression or differentiation into benign ganglioneuromas.
  • The differentiation therapy is a respective method in the clinical treatment of NB.
  • OBJECTIVE: Interferon-gamma (IFN-gamma), nerve growth factor (NGF), and combination of IFN-gamma and NGF were used as induction drugs respectively to induce the differentiation of human SMS-KCNR cells.
  • RESULTS: The simultaneous loading of NGF with IFN-gamma caused more prominent neurite outgrowth than independent treatment with either IFN-gamma or NGF in SMS-KCNR cells (P < 0.01).
  • In contrast with the induction of TrkA mRNA expression by IFN-gamma, the combination treatment could decrease TrkA mRNA expression, which might indicate that a kind of negative feedback mechanism existed.
  • These data suggest that using IFN-gamma and NGF together may be an appropriate strategy in the treatment of children with advanced neuroblastoma.
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Neuroblastoma / genetics. Neuroblastoma / pathology. RNA, Messenger / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15144710.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma; 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA
  •  go-up   go-down


34. Cerveny L, Pavek P, Malakova J, Staud F, Fendrich Z: Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia; 2006 Mar;47(3):461-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In epileptogenic brain tumors such as ganglioma, astrocytoma, anaplastic astrocytomas, or glioma multiforme, strong expression of BCRP in the microvasculature of the BBB was observed.
  • Therefore it was hypothesized that this phenomenon could critically influence the bioavailability of drugs in these tumors and potentially contribute to the failure of antiepileptic treatment.
  • The aim of this study was to test whether some commonly used antiepileptic drugs (AEDs) are substrates transported by human BCRP.
  • For detection of inhibitory potency of AEDs to BCRP, accumulation assays were carried out in MEF3.8-BCRP cells with known BCRP substrates, BODIPY FL prazosin and mitoxantrone.
  • Therefore these drugs in relevant therapeutic concentrations are neither substrates nor inhibitors of BCRP.
  • CONCLUSIONS: Based on our in vitro data we can conclude that resistance to treatment with the tested AEDs probably is not caused by the overexpression of BCRP in the BBB of epileptogenic brain tumors.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Anticonvulsants / pharmacokinetics. Blood-Brain Barrier / metabolism. Drug Resistance, Multiple / drug effects. Neoplasm Proteins / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Animals. Biological Availability. Capillary Permeability / drug effects. Cells, Cultured. Drug Interactions. Endothelial Cells / drug effects. Endothelial Cells / metabolism. Epilepsy / drug therapy. Epilepsy / metabolism. Humans. In Vitro Techniques. Mice. Mice, Knockout. Transfection

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529607.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Anticonvulsants; 0 / Neoplasm Proteins
  •  go-up   go-down






Advertisement